Premature ovarian insufficiency (POI) refers to the occurrence of ovarian hypofunction in women before the age of 40, which seriously affects women's overall health and quality of life. However, there is currently insufficient understanding of the risk factors, pathogenesis, short-term and long-term health effects of POI, and the health effects of the disease, and there is a lack of high-quality evidence to support clinical diagnosis and treatment decisions. This study intends to construct a hospital-based multi-center POI case-control and prospective special disease cohort, after baseline assessment and follow-up monitoring, collect disease characteristics, lifestyle, social psychology, environmental and occupational exposure, biological samples and other data, aiming to observe POI The natural occurrence, progression and health impact of POI, clarify the risk factors of POI, evaluate the impact of POI on women's health and disease risk, and discuss the benefits, risks and options of HRT for POI patients. The results of this study will deepen and expand the understanding of the occurrence and development of POI and its short-term and long-term health effects, provide high-level evidence for optimizing POI prevention, diagnosis and treatment strategies, and establish a long-term management system, laying the foundation for interventional research.
Age range
10 Years – 65 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Bone density
Timeframe: Baseline, 12 months, 24 months, 36 months
β-collagen degradation products
Timeframe: Baseline, 12 months, 24 months, 36 months
Osteocalcin
Timeframe: Baseline, 12 months, 24 months, 36 months
Total type I collagen amino-terminal propeptide
Timeframe: Baseline, 12 months, 24 months, 36 months
Reproductive hormones
Timeframe: Baseline, 6 months, 12 months, 24 months, 36 months
Thyroid function test
Timeframe: Baseline, 12 months, 24 months, 36 months
Symptoms related to low estrogen
Timeframe: Baseline, 6 months, 12 months, 24 months, 36 months
Sexual life
Timeframe: Baseline, 12 months, 24 months, 36 months
Fasting blood glucose
Timeframe: Baseline, 6 months, 12 months, 24 months, 36 months
Insulin
Timeframe: Baseline, 6 months, 12 months, 24 months, 36 months
Depressive symptoms
Timeframe: Baseline, 6 months, 12 months, 24 months, 36 months
Anxiety
Timeframe: Baseline, 6 months, 12 months, 24 months, 36 months
Subjective psychological well-being
Timeframe: Baseline, 6 months, 12 months, 24 months, 36 months
Number of Participants with Affected Hepatic Function Tests After Treatment
Timeframe: Baseline, 6 months, 12 months, 24 months, 36 months
Number of Participants with Affected Renal Function Tests After Treatment
Timeframe: Baseline, 6 months, 12 months, 24 months, 36 months